Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0493 in Obese Patients
NCT00482196Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0493 in obesity (4 arms), sponsored by Merck & Co. Primary endpoint: Change in Body Weight at 18 weeks. Started Jul 2005; status: completed.
02
Drugs
MK-0493
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00482196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482196.